| Abstrakt: |
A recent report from Shanghai Jiao Tong University discusses the findings of a phase III clinical trial on the treatment of extensive stage small cell lung cancer (SCLC). The study focused on the combination of Socazolimab, an anti-PDL1 antibody, with carboplatin and etoposide chemotherapy. The trial involved 498 patients with an average age of 61.9, and the primary endpoint was overall survival (OS). The results showed that the study group had a median OS of 13.90 months, compared to 11.58 months in the control group. The study suggests that Socazolimab plus chemotherapy can provide improvements in OS for patients with extensive stage SCLC. [Extracted from the article] |
